<DOC>
	<DOCNO>NCT00303485</DOCNO>
	<brief_summary>This study determine rapidity suppression bone resorption marker sCTX post-menopausal woman osteoporosis.Other bone turnover marker also evaluate . Patients randomise either monthly Boniva 150mg placebo , combination vitamin D calcium supplementation . The anticipated time study treatment approximately 7 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Bone Turnover Markers Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva ( Ibandronate )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>woman newly diagnose postmenopausal osteoporosis , require treatment ; naive bisphosphonate treatment , bisphosphonate treatment maximum 3 month , least 5 year screen . patient hormone replacement therapy ( HRT ) within last 3 month ; patient osteoporosis medication within last 3 month ; sCTX low limit , 3 time upper limit , normal premenopausal level ; hypersensitivity component ibandronate ; contraindication calcium vitamin D therapy ; history major gastrointestinal upset ; malignant disease diagnose within previous 10 year ( except resect basal cell cancer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>